|
Volumn 20, Issue 4, 2012, Pages 1442-1460
|
Angiogenesis inhibitors identified by cell-based high-throughput screening: Synthesis, structure-activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation
|
Author keywords
3 (E) styryl benzamide; Angiogenesis; Endothelial cell; HUVEC
|
Indexed keywords
1 [3 [(4 CHLOROPHENOXY)METHYL] 4 METHOXYPHENYL]ETHANONE;
1 [4 METHOXY 3 [(3 METHYLPHENOXY)METHYL]PHENYL]ETHANONE;
1 CHLORO 4 [(5 ETHYL 2 METHOXYPHENYL)METHOXY] 2 METHYLBENZENE;
3 (DIETHOXYPHOSPHORYLMETHYL) 4 METHOXYBENZAMIDE;
3 (DIETHOXYPHOSPHORYLMETHYL) 4 METHOXYBENZOIC ACID;
3 [(4 CHLORO 3 METHYLPHENOXY)METHYL] 4 METHOXYBENZAMIDE;
3 [(4 CHLORO 3 METHYLPHENOXY)METHYL] 4 METHOXYBENZONITRILE;
3 [(4 CHLORO 3 METHYLPHENOXY)METHYL]BENZONITRILE;
3 [(4 CHLORO 3 METHYLPHENOXYMETHYL)] 4 METHOXYBENZOIC ACID;
3 [(4 CHLOROPHENOXY)METHYL] 4 METHOXYBENZAMIDE;
3 [(4 CHLOROPHENYL)CARBAMOYL] 4 METHOXYBENZOIC ACID;
3 [2 (4 BROMOPHENYL)VINYL] 4 METHOXYBENZAMIDE;
3 [2 (4 TERT BUTYLPHENYL)VINYL] 4 METHOXYBENZAMIDE;
3 [STYRYL]BENZAMIDE DERIVATIVE;
4 METHOXY 3 [2 (4 TOLYL)VINYL]BENZAMIDE;
5 ETHOXYCARBONYL 2 METHOXYBENZOIC ACID;
ANGIOGENESIS INHIBITOR;
BENZAMIDE DERIVATIVE;
ETHYL 3 (CHLOROMETHYL) 4 METHOXYBENZOIC ACID;
ETHYL 3 (DIETHOXYPHOSPHORYLMETHYL) 4 METHOXYBENZOIC ACID;
ETHYL 3 [(4 CHLORO 3 METHYLPHENOXYMETHYL)] 4 METHOXYBENZOIC ACID;
ETHYL 3 [(4 CHLOROPHENOXYMETHYL)] 4 METHOXYBENZOIC ACID;
ETHYL 3 [(4 CHLOROPHENYL)CARBAMOYL] 4 METHOXYBENZOIC ACID;
ETHYL 3 [2 (4 CHLOROPHENYL)VINYL] 4 METHOXYBENZOIC ACID;
ETHYL 3 FORMYL 4 HYDROXYBENZOIC ACID;
ETHYL 3 FORMYL 4 METHOXYBENZOIC ACID;
METHYL 3 [(4 CHLORO 3 METHYLPHENOXY)METHYL] 4 METHOXYBENZOIC ACID;
RO 0123743;
SUNITINIB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANGIOGENESIS;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANTIANGIOGENIC ACTIVITY;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
CELL DENSITY;
CELL PROLIFERATION;
CHIRALITY;
CONTROLLED STUDY;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG CYTOTOXICITY;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG SCREENING;
DRUG SELECTIVITY;
DRUG SOLUBILITY;
DRUG SYNTHESIS;
ENDOTHELIUM CELL;
FEMALE;
HIGH THROUGHPUT SCREENING;
HUMAN;
HUMAN CELL;
MAXIMUM PLASMA CONCENTRATION;
MELTING POINT;
MICROVASCULATURE;
MOUSE;
NONHUMAN;
PROCESS OPTIMIZATION;
PROTEIN PHOSPHORYLATION;
PROTON NUCLEAR MAGNETIC RESONANCE;
STRUCTURE ACTIVITY RELATION;
TIME TO MAXIMUM PLASMA CONCENTRATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BENZAMIDES;
BENZYL COMPOUNDS;
CELL LINE, TUMOR;
CELL PROLIFERATION;
ENDOTHELIAL CELLS;
HUMANS;
PHENYL ETHERS;
STRUCTURE-ACTIVITY RELATIONSHIP;
STYRENES;
XENOGRAFT MODEL ANTITUMOR ASSAYS;
|
EID: 84857033040
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2011.12.058 Document Type: Article |
Times cited : (13)
|
References (31)
|